TY - JOUR
T1 - Neuro-oncology and radiogenomics
T2 - Time to integrate?
AU - Lasocki, A.
AU - Rosenthal, M. A.
AU - Roberts-Thomson, S. J.
AU - Neal, A.
AU - Drummond, K. J.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Radiogenomics aims to predict genetic markers based on imaging features. The critical importance of molecular markers in the diagnosis and management of intracranial gliomas has led to a rapid growth in radiogenomics research, with progressively increasing complexity. Despite the advances in the techniques being examined, there has been little translation into the clinical domain. This has resulted in a growing disconnect between cutting-edge research and assimilation into clinical practice, though the fundamental goal is for these techniques to improve patient care. The goal of this review, therefore, is to discuss possible clinical scenarios in which the addition of radiogenomics may aid patient management. This includes facilitating patient counseling, determining optimal patient management when complete molecular characterization is not possible, reclassifying tumors, and overcoming some of the limitations of histologic assessment. The review also discusses considerations for selecting relevant radiogenomic features based on the clinical setting.
AB - Radiogenomics aims to predict genetic markers based on imaging features. The critical importance of molecular markers in the diagnosis and management of intracranial gliomas has led to a rapid growth in radiogenomics research, with progressively increasing complexity. Despite the advances in the techniques being examined, there has been little translation into the clinical domain. This has resulted in a growing disconnect between cutting-edge research and assimilation into clinical practice, though the fundamental goal is for these techniques to improve patient care. The goal of this review, therefore, is to discuss possible clinical scenarios in which the addition of radiogenomics may aid patient management. This includes facilitating patient counseling, determining optimal patient management when complete molecular characterization is not possible, reclassifying tumors, and overcoming some of the limitations of histologic assessment. The review also discusses considerations for selecting relevant radiogenomic features based on the clinical setting.
UR - http://www.scopus.com/inward/record.url?scp=85096059893&partnerID=8YFLogxK
U2 - 10.3174/ajnr.A6769
DO - 10.3174/ajnr.A6769
M3 - Review Article
C2 - 32912874
AN - SCOPUS:85096059893
SN - 0195-6108
VL - 41
SP - 1982
EP - 1988
JO - American Journal of Neuroradiology
JF - American Journal of Neuroradiology
IS - 11
ER -